Foresite Capital Management VI LLC
Regulatory profile
From Form ADV, the SEC filer profile, 13D/13G type codes and N-CEN, never from the name.
Portfolio style
Measured from the filed 13F common-share book for Jun 30, 2026, never from the firm's own description.
Closest benchmark: the Russell 2000 as of 2026-06-30, active share 98.7%; sector active share 90.4% against the combined 13F book's sector weights.
Over time 7 measured quarters
How the bands are measured
Style bands measure the filed 13F common-share book each closed quarter, tested in this order. Unknown: under $10,000,000 of valued equity or 5 stocks. Index-like (100+ stocks): active share of 20% or less against the closest benchmark, which is the S&P 500, S&P MidCap 400, S&P SmallCap 600, Russell 1000, Russell 2000, Nasdaq-100 or Dow Jones Industrial Average (weighted by an index-tracking fund's reported holdings or the index's constituents nearest the quarter end, over the names resolved to companies, and only when those are 90%+ of its weight) or every 13F filer's combined book, or index series holding 80%+ of the registered fund assets it advises (N-CEN) and equal to 50%+ of its book. Systematic-like: 500+ stocks, 100%+ annual turnover and a top 10 weight of 25% or less. Concentrated: a top 10 weight of 60%+ or 12 or fewer effective positions. Diversified active: none of these. Turnover is the smaller of buys and sells over average equity value, summed over four quarters: low under 30%, high 100%+. Horizon is the value-weighted number of quarters each position has been held: short under 4, long 12+.
Clone Performance
Build a hypothetical price-return history from this filer's public 13F holdings.
View clone backtestPortfolio Concentration
23 tracked positions · as of Jun 30, 2026 · Δ vs Mar 31, 2026Portfolio Trend
Sector Breakdown
As of Jun 30, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 99.5% | $639,365,979 |
| Financial Services | 0.5% | $3,210,000 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| GHRS | GH Research PLC | +625,001 | 940,493 | $25,280,451 | |
| JBIO | Jade Biosciences, Inc. | +566,667 | 886,667 | $19,701,740 | |
| CLDX | Celldex Therapeutics, Inc. | +563,800 | 879,713 | $32,734,120 | |
| AGIO | Agios Pharmaceuticals, Inc. | +260,000 | 785,000 | $29,131,350 | |
| DNLI | Denali Therapeutics Inc. | +186,800 | 1,396,771 | $35,924,950 | |
| CGON | CG Oncology, Inc. | +148,100 | 2,369,574 | $168,358,232 | |
| No positions match the current search. | |||||
Trimmed
Positions the filer reduced| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| NERV | Minerva Neurosciences, Inc. | −1,016 | 1,985,584 | $11,019,991 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| SPTX | Seaport Therapeutics, Inc. | 1,779,521 | $38,651,196 | |
| PBLS | Parabilis Medicines, Inc. | 999,044 | $27,343,834 | |
| BEAM | Beam Therapeutics Inc. | 330,000 | $11,325,600 | |
| AVBP | ArriVent BioPharma, Inc. | 301,341 | $10,468,586 | |
| AURA | Aura Biosciences, Inc. | 1,333,334 | $9,466,671 | |
| RACC | Research Alliance Corp III | 300,000 | $3,210,000 | |
| KLRA | Kailera Therapeutics, Inc. | 37,500 | $826,125 | |
| IRON | Disc Medicine, Inc. | 970 | $70,945 | |
| No positions match the current search. | ||||
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| CGON |
CG Oncology, Inc.
Healthcare
|
Added | 2,369,574 | $168,358,232 | 26.20% | |
| ALMS |
Alumis Inc.
Healthcare
|
Held | 4,247,670 | $119,529,433 | 18.60% | |
| SPTX |
Seaport Therapeutics, Inc.
Healthcare
|
NEW | 1,779,521 | $38,651,196 | 6.02% | |
| DNLI |
Denali Therapeutics Inc.
Healthcare
|
Added | 1,396,771 | $35,924,950 | 5.59% | |
| CLDX |
Celldex Therapeutics, Inc.
Healthcare
|
Added | 879,713 | $32,734,120 | 5.09% | |
| AGIO |
Agios Pharmaceuticals, Inc.
Healthcare
|
Added | 785,000 | $29,131,350 | 4.53% | |
| CRVS |
Corvus Pharmaceuticals, Inc.
Healthcare
|
Held | 1,831,233 | $27,358,621 | 4.26% | |
| PBLS |
Parabilis Medicines, Inc.
Healthcare
|
NEW | 999,044 | $27,343,834 | 4.26% | |
| GHRS |
GH Research PLC
Healthcare
|
Added | 940,493 | $25,280,451 | 3.93% | |
| JBIO |
Jade Biosciences, Inc.
Healthcare
|
Added | 886,667 | $19,701,740 | 3.07% | |
| HNGE |
Hinge Health, Inc.
Healthcare
|
Held | 220,400 | $18,293,200 | 2.85% | |
| KYMR |
Kymera Therapeutics, Inc.
Healthcare
|
Held | 146,332 | $16,779,890 | 2.61% | |
|
|
Held | 2,750,000 | $14,492,500 | 2.26% | ||
| VSTM |
Verastem, Inc.
Healthcare
|
Held | 3,146,631 | $12,020,130 | 1.87% | |
| BEAM |
Beam Therapeutics Inc.
Healthcare
|
NEW | 330,000 | $11,325,600 | 1.76% | |
| NERV |
Minerva Neurosciences, Inc.
Healthcare
|
Reduced | 1,985,584 | $11,019,991 | 1.71% | |
| AVBP |
ArriVent BioPharma, Inc.
Healthcare
|
NEW | 301,341 | $10,468,586 | 1.63% | |
| AURA |
Aura Biosciences, Inc.
Healthcare
|
NEW | 1,333,334 | $9,466,671 | 1.47% | |
|
|
Held | 212,010 | $7,933,414 | 1.23% | ||
| RACC |
Research Alliance Corp III
Financial Services
|
NEW | 300,000 | $3,210,000 | 0.50% | |
| ZURA |
Zura Bio Ltd
Healthcare
|
Held | 450,000 | $2,655,000 | 0.41% | |
| KLRA |
Kailera Therapeutics, Inc.
Healthcare
|
NEW | 37,500 | $826,125 | 0.13% | |
| IRON |
Disc Medicine, Inc.
Healthcare
|
NEW | 970 | $70,945 | 0.01% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.